A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer

The purpose of this study is to see if the study drug,amivantamab (also known as Rybrevant TM) is safe and useful for treating patients with Colorectal Cancer (CRC) when it is given alone or in addition to standard-of-care chemotherapies (mFOLFOX6 or FOLFIRI), as well as to find the best dose of amivantamab when given with chemotherapies. Amivantamab is an antibody made from a protein, designed to target and eliminate a specific harmful object in your body, in this case, a cancer cell. Amivantamab works by targeting a protein in your body known as epidermal growth factor receptor (EGFR), that when present at elevated levels in your body can cause your cancer to worsen. Please note that amivantamab is not approved by the United States Food and Drug Administration for the treatment of colorectal cancer.

Are you Eligible? (Inclusion Criteria)

• You must be 18 years of age or older to participate. -You must have progressed on chemotherapy. -You must have been diagnosed with metastatic colorectal cancer. -You must be willing to receive the study treatment through a vein in your arm